Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib or Regorafenib in HCC After Immunotherapy (REVIVE)
NCT07495579Phase 2Not yet recruiting
- Sponsor
- Asan Medical Center
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, regorafenib in hepatocellular carcinoma (HCC), sponsored by Asan Medical Center. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
lenvatinibregorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07495579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07495579.